As a potent anti-colorectal cancer (CRC) agent, CUR targets multiple signaling pathways: it suppresses STAT3 and NF-κB activity, thereby downregulating downstream effectors (e.g., COX-2, cyclin D1, Bcl-2, and Bcl-XL). This evidence concerns the gene CCND1 and colorectal carcinoma.